Articles tagged with Leukemia
A new study reveals that babies who develop leukemia during the first year of life inherit a strong genetic predisposition to the disease. The research found that infants with leukemia have an excess of damaging changes in genes linked to leukemia, which can be passed from both parents.
A team of researchers at the University of Montreal has discovered a promising new approach to treating leukemia by targeting the Brg1 gene. The study found that removing or inhibiting this gene can permanently shut down cancerous cell growth and division.
Researchers aim to make blood cancers more vulnerable to treatment by targeting the hiding spots where leukemia cells reside. Initial focus is on blood vessels, which provide a safe haven for these cells.
Researchers have created an artificial bone marrow that can reproduce hematopoietic stem cells, which could facilitate the treatment of leukemia. The new technology uses synthetic polymers and protein building blocks to mimic the natural environment of bone marrow, allowing for more efficient stem cell reproduction.
Researchers identify two therapeutic targets to block cancer cell growth: PAK and STAT5. The shutdown of either target significantly delays leukemia progression in mice, offering new hope for cancer treatment.
Researchers have developed genetically engineered cell therapies demonstrating early efficacy and safety in patients with blood disorders. The treatments use a patient's own re-engineered cells to attack their disease, offering an innovative approach to precision medicine.
Researchers found that LIF levels are predictive of NPC patient response to radiation therapy, with patients resistant to treatment having higher serum levels of the cytokine. LIF promotes NPC progression and radioresistance.
Researchers have found a rare case where a bone marrow transplant cured a child's peanut allergy. The study suggests genetic modification during immune cell development may play a role in causing allergies.
A recent EORTC trial found that detecting ERG gene deletion at diagnosis of childhood B-cell precursor acute lymphoblastic leukemia (ALL) is beneficial for risk stratification. Patients with the ERG gene deletion had an 8-year event-free survival rate of 86.4% and overall survival of 95.6%.
Researchers at UAlberta have discovered a potential new treatment for colitis by using a leukemia drug to reverse symptoms in lab tests. The discovery suggests that inhibiting inflammation can reduce the likelihood of patients with ulcerative colitis developing colorectal cancer later in life.
Thomas Kipps, MD, PhD, receives a 5-year, $6.25 million grant from The Leukemia & Lymphoma Society to support research on chronic lymphocytic leukemia (CLL). The grant aims to identify potential new therapies that target identified pathways supporting leukemia-cell survival.
Researchers identified a gene mutation that predisposes children to the most common form of childhood leukemia. The PAX5 mutation was found in multiple generations of two families, leading to a marked reduction of normal PAX5 activity in leukemia cells.
Researchers uncover how ABL regulatory unit controls cell fate in CML, with implications for cancer treatment. The study finds that anchoring ABL on the cell membrane is essential for apoptosis, highlighting a potential target for novel therapies.
Researchers have developed unique virus-derived particles that can kill human blood cancer cells in the laboratory and eradicate the disease in mice. These non-replicating particles, derived from rhabdovirus, work by direct cytolysis and induction of antitumor immunity, showing promise as a new therapy for leukemia.
A study suggests blocking part of a DNA repair complex can increase chemotherapy effectiveness and enhance survival in therapy-resistant leukemia. Researchers found that combining mTOR inhibitors with chemotherapy was far more effective at treating T-cell acute lymphoblastic leukemia (T-ALL) than standalone treatments.
A new vaccine has shown promise in boosting the immune system's ability to attack leukemia cells in post-transplant patients. The personalized tumor vaccine, which includes the patient's own irradiated leukemia cells combined with an immune stimulant, has been shown to induce a strong and selective immune response.
Researchers discovered a mutated protein that selectively enhances cancer cells while sparing healthy ones. The findings suggest a potent new therapeutic target for certain types of leukemia.
Researchers at Scripps Research Institute receive $1.4 million from the National Cancer Institute to create a potential new drug targeting malignant cells in CLL, while sparing normal tissues. The study aims to deliver cytotoxic drugs with specific targeting using cell surface receptor TOSO and receptor tyrosine kinase ROR1.
A study led by St. Jude Children's Research Hospital found that epigenetic changes, such as cytosine methylation, are unique to each child with ALL and may be as important as genetic alterations in causing the disease. The research suggests that epigenetic targeted therapies could be developed for patients with ALL.
Researchers identified unique properties of normal MLL1 pathway in hematopoietic stem cells that may be exploited to treat leukemia with MLL1 translocations. This could lead to improved transplantation outcomes for chemotherapy-resistant cancers.
A recent study revealed a new mutation in atypical chronic neutrophilic leukemia (CNL) patients, allowing doctors to prescribe targeted treatment ruxolitinib. The treatment brought significant improvements to the patient's health, including reduced white blood cell counts and normalized other blood counts.
Researchers at Children's Hospital of Philadelphia report complete remission in two pediatric ALL patients treated with novel cell therapy. The treatment, known as CTL019, uses engineered T cells that target a specific protein on the surface of leukemia cells, achieving a potent anticancer effect.
A novel T-cell therapy has demonstrated complete remission in two pediatric patients with acute lymphoblastic leukemia (ALL), a high-risk type of cancer. The treatment, which reprograms the immune cells to target specific cancer cells, has shown promising results but also carries potential side effects.
Scientists have identified a molecule called Gfi1 that represents the disease's Achilles' heel and could be targeted to develop a new approach. This discovery has direct implications for the treatment of acute lymphoblastic leukemia, a cancer of the bone marrow and blood that progresses rapidly.
An international research team has discovered a possible alternative treatment for lymphoid leukemia that eradicated the disease in mouse models. The targeted molecular therapy could make leukemia more susceptible to chemo and radiation therapies, benefiting patients with Acute Lymphoid Leukemia (ALL).
Researchers have identified 7 new genes with a key role in T-ALL, a form of leukemia primarily affecting children. The study also found that defects in the ribosome can play a role in cancer activation, offering potential new targets for treatment.
Researchers identified a possible hereditary mechanism for childhood leukemia, linking a genetic defect in sex cells to the disease. The study found that atypical forms of the PRDM9 gene variant increase children's risk of developing acute lymphoblastic leukemia.
Researchers at Baylor College of Medicine have discovered a vegetable compound that can reduce the number of acute lymphoblastic leukemia cells. Sulforaphane, found in broccoli and other cruciferous vegetables, was shown to kill cancer cells while leaving healthy cells unaffected in lab tests.
Researchers found that a weekly dose of the targeted drug inotuzumab ozogamicin reduces side effects and maintains its effectiveness against acute lymphocytic leukemia (ALL) in patients. The treatment showed an overall response rate of 57% with manageable toxicities.
A Phase 2 clinical trial found that combining ibrutinib and rituximab produced profound responses in high-risk CLL patients with minimal side effects. Researchers hope to further develop the treatment for this aggressive form of leukemia.
Researchers at Children's Hospital of Philadelphia use bioengineered T cells to destroy leukemia cells, achieving a complete response in a 7-year-old girl. The treatment, known as CTL019, also stimulates an immune response and can be combined with immunomodulating drugs to reduce side effects.
Researchers at Ohio State University Wexner Medical Center discovered that high levels of interleukin-15 can cause large granular lymphocytic leukemia, a rare and usually fatal form of cancer. The study led to the development of a treatment with no discernible side effects.
Researchers have identified potential new prognostic biomarkers and therapeutic targets for adult B-acute lymphoblastic leukemia. A study found that changes in the epigenetic code are linked to aggressive traits in the disease.
Researchers have developed a new technique to study how myeloids become white blood cells, providing new insights into the molecular mechanisms at work during this process. This approach offers potential improvements in treating myeloid diseases like leukemia by identifying key regulatory pathways and developing therapeutic strategies.
Scientists have developed a new video protocol to isolate brain tumor initiating stem cells from primary brain tumors, allowing for quick and efficient analysis of target cells. This approach has been effectively used to identify similar stem cells in leukemia patients.
Researchers at Northwestern University have identified two promising therapies to treat AMKL: alisertib and dimethylfasudil. Alisertib targets Aurora A kinase and shows promise in mouse models, while dimethylfasudil boosts mature bone marrow cells and inhibits malignant ones.
Researchers tested blood samples from 300 people for the presence of XMRV and pMLV genes, eliminating potential contamination that led to earlier false positives. No correlation between these viruses and chronic fatigue syndrome was found, refuting previous speculation.
Researchers at URMC have identified a new genetic signature for leukemia that can be used to target rogue cells. They found approximately 70 genes associated with the growth and survival of leukemia cells, opening up new avenues for drug discovery.
Researchers identified 38 prognostic subnetworks of interacting genes that predict cancer progression in chronic lymphocytic leukemia. The study helps define how CLL evolves over time, becoming more aggressive and deadly.
Researchers at the University of Cincinnati discovered a new gene target for leukemia therapy by inhibiting the protein Vav3, which controls cell signaling. This finding could lead to cellular targets for patients with BCR-ABL lymphoid leukemia, a type of leukemia with poor treatment outcomes.
A new study led by University of Rochester Medical Center researcher Barbara L. Asselin shows that giving a cardio-protective drug during cancer treatment may prevent damage to the hearts of childhood leukemia survivors. The study found that the drug Zinecard significantly reduced heart problems and damage in patients who received it.
Researchers at Ohio State University have identified a 'life-and-death' molecule on the surface of chronic leukemia cells that targets CD37. The finding could lead to more effective therapy for CLL, an as yet incurable cancer that occurs in over 16,000 Americans annually.
Researchers discovered that 40% of LGL patients have a STAT3 mutation, which may aid in diagnosing and treating the disease. The mutation is also associated with an increased risk of rheumatoid arthritis, opening new avenues for understanding its pathogenesis.
A phase I/II clinical trial indicates that older patients with chronic lymphocytic leukemia respond well to the experimental drug ibrutinib, which has few side effects and a high one-year survival rate. The study suggests that ibrutinib deserves further testing as a first-line therapy for elderly CLL patients.
A study has found that high-throughput sequencing can detect minimal residual disease in nearly double the number of leukemia patients as current gold standard method. This technology offers a greater chance of survival by predicting disease relapse sooner.
Researchers at UCSD School of Medicine identified G protein-coupled receptors as potential biomarkers and therapeutic targets for chronic lymphocytic leukemia. The expression of specific GPCRs, such as VIPR1, is linked to disease stage and prognosis.
Researchers have identified microRNA-155 as a molecule that controls the severity of acute graft-versus-host disease in leukemia patients who receive bone-marrow transplants. Reducing or blocking miR-155 expression decreases GVHD severity and increases survival, suggesting a new strategy for treating the condition.
A team of researchers at Case Western Reserve University School of Medicine has developed a new theranostic agent for the treatment of acute lymphoblastic leukemia (ALL). The agent combines a diagnostic test with targeted therapy to provide personalized treatments for pediatric leukemia.
Yale researchers found that megakaryocytes grow 10-15 times larger than other blood cells through endomitosis, but a malfunction in this process may lead to leukemia. The discovery reveals the formation of functional platelets and provides clues about what may go awry to transform normal megakaryocytes into malignant leukemia cells.
A study in a mouse model of Down syndrome identifies increased expression of protein Dyrk1a as a promoter of acute megakaryoblastic leukemia, offering a candidate therapeutic target for treatment.
Research identifies increased expression of Dyrk1a as a potential explanation for the increased risk of acute megakaryoblastic leukemia (AMKL) in children with Down syndrome. A candidate therapeutic target, small-molecule inhibitors of DYRK1A activity, have been proposed.
Research identifies SIRT1 as a key enzyme protecting leukemia stem cells from stress and driving cancer recurrence. Inhibiting SIRT1 selectively reduces CML stem cell survival and growth, offering a potential therapeutic target for treatment resistance.
Researchers at URMC discovered a link between leukemia cells and bone formation, finding that leukemia alters the balance of osteoblast and osteoclast activity. The study suggests that targeting osteoclasts could be a potential treatment strategy for leukemia.
Researchers found that blocking HSP90 activity renders protected proteins vulnerable to destruction, slowing the growth of MIF-expressing breast tumors. HSP90 inhibitors also showed promise in slowing leukemia cell growth driven by hyperactive JAK2 enzyme versions.
A team of researchers identified genetic mutations in OATP1B1 and OATP1B3 as the cause of Rotor syndrome, a rare genetic disorder characterized by jaundice. Complete deficiency of these proteins causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.
A Penn State research team has discovered a compound produced from fish oil that targets and kills leukemia stem cells, potentially leading to a cure for the disease. The compound, D12-PGJ3, selectively activates a gene in leukemia stem cells that programs their own death.
Researchers discovered nine frequently mutated genes in CLL that may help predict disease progression and guide treatment. The study identified new cancer pathway aberrant RNA splicing, which could lead to novel targeted treatments.
A phase Ib/II clinical trial reveals that PCI-32765 is highly active and well-tolerated in 61 relapsed CLL patients, with 70% achieving complete or partial remission after 10 months of treatment. The agent targets Bruton's tyrosine kinase, a key protein for CLL-cell survival.
A study published in Blood has identified a potential marker, PD-1, that is more frequently found in young leukemia patients who experience relapses. This discovery could lead to the development of simple tests to predict relapse, reducing the risk for these vulnerable individuals.
Researchers at Princess Margaret Cancer Program have identified a promising approach to treating leukemia using the antibiotic tigecycline. By cutting off energy production in leukemia stem cells, the drug can selectively destroy these cancerous cells while sparing healthy ones.